We appreciated reading the article by Zhang et al[1] about a retrospective study of 102 mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients with epilepsy in which disability and...We appreciated reading the article by Zhang et al[1] about a retrospective study of 102 mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients with epilepsy in which disability and outcome were assessed (median follow-up: 4 years). Administration of levetirazetam (LEV) was associated with a better outcome compared to other antiepileptic drugs (AEDs).[1] The study has several shortcomings requiring discussion.展开更多
文摘We appreciated reading the article by Zhang et al[1] about a retrospective study of 102 mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients with epilepsy in which disability and outcome were assessed (median follow-up: 4 years). Administration of levetirazetam (LEV) was associated with a better outcome compared to other antiepileptic drugs (AEDs).[1] The study has several shortcomings requiring discussion.
